



10100 Dr. M.L. King Jr. St. N.
St. Petersburg, FL 33716
Phone: (727) 568-1213

PRESS RELEASE

Contact: Thomas McLain
Claro Scientific, LLC
thomas.mclain@clarosci.com

Claro Scientific Selected as Region's Top Early Stage Investment at 2011 Southeast Bio Investor Forum

St. Petersburg, FL--(November 16, 2011) — Claro Scientific announced today that it won the highly regarded 'EARLY/Stage Shootout' competition at Southeast Bio's 13th Annual Investor Forum held in Durham, North Carolina.

The SEBIO Investor Forum is the Southeast region's premier life sciences venture capital conference, connecting growing life science companies with potential investors in a forum that also provides meaningful networking opportunities. Attracting 400 attendees, including investors from across the United States, SEBIO showcased 28 life sciences companies from Alabama, Florida, Georgia, North Carolina, South Carolina, Tennessee and Virginia. SEBIO participants have gone on to raise over \$2.5 billion in public and private funding.

"Judges from nationally recognized venture funds, including Hatteras, H.I.G., Intersouth and NEA, selected Claro Scientific as the EARLY/stage company winner based on the effectiveness of their presentation, the viability of the venture, and fundability of the opportunity," said Jennifer Moore, Ph.D., Executive Director of Southeast BIO. "This kind of validation along with the significant exposure to the broader business community has served past EARLY/Stage winners well by helping them excel to their next phase of company development."

Claro Scientific was selected from among 60 early-stage medical device, drug and biotechnology companies. The company is advancing SpectraWave, a low cost, easy to use point of care diagnostic system that uses light to analyze samples and deliver results in less than five minutes. Claro licensed the technology from the University of South Florida in Tampa, FL. Clinical studies in 2011 have demonstrated that SpectraWave can identify bacteria causing severe and often fatal hospital infections with a high degree of accuracy. Previous clinical proof of concept studies have demonstrated SpectraWave's value for analyzing blood and urine samples and measuring important health markers. The system can be used in laboratories, physician offices, clinics, long term care facilities or even remote locations without any healthcare infrastructure. Claro's goal is to make actionable information available to patients and healthcare workers in minutes to improve outcomes and manage long term health.

Robert Crutchfield, a partner with Harbert Venture Partners in Birmingham, AL was on an eight member panel that evaluated and provided feedback to Claro and three other early stage companies on their elevator pitch, presentation and business plan during the first day of the conference. In commenting on what makes Claro attractive for venture capital investors, he observed "Claro Scientific's optical diagnostic technology has the potential to provide game changing, true point of care diagnostic results, in real time, without assays or reagents."

About Claro Scientific, LLC

Claro Scientific has developed SpectraWave™, a portable, reagentless diagnostic system that delivers actionable results in less than five minutes. Through clinical studies, Claro has demonstrated its value for pathogen identification by achieving a very high degree of sensitivity and specificity. SpectraWave will redefine medical care by bringing complex laboratory testing to the patient in a low cost and process efficient way. SpectraWave products have significant competitive advantages in several commercial markets including medical diagnostics and personalized health monitoring. For further information, please visit: www.clarosci.com.

About Southeast BIO

Southeast BIO (SEBIO) is a regional nonprofit organization that fosters the growth of the life sciences industry in the Southeastern United States through efforts that promote entrepreneurship and bring together companies, investors, universities, and support organizations active in the development of the industry. A public/private partnership formed in 1999, SEBIO is committed to conducting activities that create regional leverage and facilitate the common interests and goals of constituents in the life sciences industry. SEBIO's geographic footprint includes Alabama, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. For further information, visit www.sebio.org.

###